Together, these data support a model in which YY1 may contribute to BC progression given its overexpression in tumor vs. normal tissue, association with more aggressive tumor and clinical phenotypes, and poor survival outcomes, making it a promising molecular biomarker and potential target for future diagnostic and therapeutic strategies. The gene discussed is YY1; the disease is neoplasm.